German pharmaceutical giant Bayer announced Wednesday its plans to acquire Perfuse Therapeutics, a biopharmaceutical company, in a transaction that could reach $2.45 billion in total value.
According to the company’s announcement, the acquisition is intended to strengthen Bayer’s eye care treatment development portfolio. The financial structure includes an initial payment of $300 million, with additional payments tied to achieving specific development, regulatory approval, and sales milestones.
The deal represents Bayer’s continued investment in expanding its medical treatment capabilities, particularly in the field of ophthalmology.
